SCHEMBL19704135

SCHEMBL19704135

CC(C)(C)C1CCN(C(=O)Oc2c(F)c(F)c(F)c(F)c2F)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.43
KCNH2 Q12809 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
NPY2R P49146 6/20 0.39
GAA P10253 1/20 0.39
EPHX2 P34913 1/20 0.38
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
HPGD P15428 1/20 0.35
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD11B1 P28845 1/20 0.35
LYPLA1 O75608 1/20 0.34
LYPLA2 O95372 1/20 0.34
GPR119 Q8TDV5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19698218 0.92 CYP2D6 (0.40) CYP2D6KCNH2HRH3NPY2RGAA
SCHEMBL19704248 0.88 CASP3 (0.41) CYP2D6KCNH2HRH3NPY2RGAA
SCHEMBL19698234 0.83 CASP3 (0.39) CYP2D6KCNH2HRH3NPY2RGAA
SCHEMBL19704125 0.81 GAA (0.57) GAAEPHX2MEN1KMT2AHPGD
SCHEMBL20034755 0.81 CYP2D6 (0.38) CYP2D6KCNH2HRH3EPHX2MEN1
SCHEMBL19704133 0.80 NPC1 (0.40) CYP2D6KCNH2HRH3EPHX2MEN1
SCHEMBL19704139 0.79 NPC1 (0.45) CYP2D6KCNH2HRH3EPHX2MEN1
SCHEMBL19698224 0.76 CYP2D6 (0.35) CYP2D6KCNH2HRH3EPHX2MEN1
SCHEMBL12040229 0.75 CYP2D6 (0.50) CYP2D6KCNH2HRH3NPY2REPHX2
SCHEMBL31718378 0.75 ALDH1A1 (0.55) GAAMEN1KMT2ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938323-B2 Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase NOVARTIS AG (CH) 2018-04-10 US disclosed
US-20170355731-A1 AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355731-A1 AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE RNGTT, RNASE1, RNMT CYP2D6 4032/4885KCNH2 3926/4885HRH3 3016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.